Hematological Indicators of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in Malaria-Infected Individuals

@#Introduction: Malaria, a life-threatening infectious disease caused by Plasmodium parasites, continues to be a major global health concern, particularly in regions with high transmission rates. This retrospective cohort study aimed to investigate the hematological indicators of G6PD deficiency in individuals infected with malaria. The study utilized medical records and laboratory test results to analyze the hematological parameters and markers in individuals with confirmed malaria and G6PD deficiency. Methods: Data were collected from the laboratory unit of Mosul Teaching Hospitals in Ninevah Province, Iraq, from March 2021 to November 2022. The study population consisted of individuals diagnosed with malaria and with available G6PD deficiency test results. G6PD deficiency was determined by measuring the G6PD enzyme activity in the patient’s blood. Hematological parameters, including complete blood counts, platelet counts, and red blood cell indices, were recorded using a laboratory information system. Results: The study population exhibited a relatively low prevalence of G6PD deficiency, with no significant differences observed in age or gender distribution between individuals with and without G6PD deficiency. The distribution of malaria types did not differ significantly between the two groups. However, patients with G6PD deficiency showed a significantly higher monocyte count, indicating a potential association between G6PD deficiency and altered monocyte response during malaria infection. The clinical significance of this finding requires further investigation. Conclusion: This study sheds light on the hematological indicators of G6PD deficiency in individuals infected with malaria. The findings suggest a potential relationship between G6PD deficiency and altered monocyte response during malaria infection.

Desarrollo y validación interna de un modelo de predicción clínica del riesgo de infección bacteriana nosocomial en pacientes con lupus eritematoso sistémico / Development and internal validation of a clinical prediction model of the risk of nosocomial bacterial infection in patients with systemic lupus erythematosus

RESUMEN Introducción: Los pacientes con lupus eritematoso sistémico (LES) tienen un riesgo aumen tado de padecer infecciones tanto adquiridas en la comunidad como asociadas con el cuidado de la salud. Las infecciones bacterianas son las más frecuentes y graves durante la hospitalización de estos pacientes. Objetivo: Desarrollar y validar internamente un modelo de predicción clínica de pronóstico del riesgo de infección bacteriana adquirida en el hospital en pacientes con LES, usando datos clínicos y de laboratorio obtenidos durante las primeras horas de hospitalización. Métodos: Se analizó una cohorte retrospectiva de pacientes con LES mayores de 16 arios, hos pitalizados por motivos diferentes a infección bacteriana en 2 hospitales de alta complejidad de Medellín entre 2011 y 2016. Se compararon las características de los pacientes que des arrollaron el desenlace de infección bacteriana entre el día 3 y el día 15 de hospitalización con aquellos que no lo presentaron. Las variables significativas en el análisis bivariado fueron consideradas para la construcción del modelo por medio de regresión logística multivariada. Resultados: Se incluyeron 765 episodios, de los cuales 98 (12,8%) presentaron el desenlace de interés. Se consideraron 35 predictores candidatos. Las variables incorporadas en el modelo final fueron: edad, recuento de neutrófilos, puntaje de actividad lúpica SLEDAI, uso de sonda vesical, uso de catéter venoso central en las primeras 72 h, dosis de glucocorticoides en el mes previo y el uso de un antimalárico en los 3 meses previos. La capacidad de discrimi nación del modelo fue aceptable a buena (AUC-ROC 0,74; IC 95% 0,69-0,80). La prueba de bondad de ajuste de Hosmer-Lemeshow (p = 0,637) evidenció una adecuada calibración. Conclusión: Desarrollamos un modelo de predicción clínica de pronóstico del riesgo de infec ción bacteriana nosocomial en pacientes con LES. El modelo desarrollado está compuesto por variables clínicas y de laboratorio simples disponibles en el momento del ingreso al hospital. Se requieren estudios de validación externa y de impacto clínico antes de su implementación rutinaria.

ABSTRACT Introduction: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing community-acquired infections, as well as those associated with health care. Bacterial infections are the most common and serious while these patients are in hospital. Objective: To develop, and internally validate, a clinical prediction model for the prognosis of the risk of hospital-acquired bacterial infection in SLE patients using clinical and laboratory data obtained during the first hours of hospital admission. Methods: An analysis was performed on retrospective cohort of patients with SLE older than 16 years and admitted for reasons other than bacterial infection in 2 highly complex hospitals in Medellín between 2011 and 2016. The characteristics of the patients who developed a bacterial infection were compared between day 3 and day 15 of hospital admission with those who did not develop one. The significant variables in the bivariate analysis were used for the construction of the model using multivariate logistic regression. Results: A total of 765 episodes were included, of which 98 (12.8%) presented the outcome of interest. Thirty-five candidate predictors were considered. The variables incorporated in the final model were: age, neutrophil count, SLEDAI lupus activity score, use of a bladder catheter, use of a central venous catheter in the first 72 h, glucocorticoid doses in the previous month, and use of an antimalarial drug in the 3 previous months. The discrimination capacity of the model was acceptable to good (AUC-ROC 0.74; 95% CI 0.69-0.80). The Hosmer-Lemeshow goodness of fit test (P = .637) suggested adequate calibration. Conclusion: A clinical prediction model of prognostic risk of nosocomial bacterial infection in patients with SLE has been developed. This model is made up of simple clinical and laboratory variables available at the time of hospital admission. External validation and clinical impact studies are required before routine implementation.

Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile

After the global pandemic of the new coronavirus, its rapid spreadand many victims, it is necessary to find an effective vaccine or drugs to overcome it. Most specialists consider that repositioning somemedications is the best, fastestand most reliable option for treating patients with the new coronavirus without delay. One of these drugs was an old antimalarial drug, hydroxychloroquine. The current review aimed to explore its potential mechanism, as well as its pharmacokinetics and toxicity, in an attempt to suggest a treatment protocol for its use in treating the COVID-19 virus effectively and safely. This study reviewed the published references on the popular search engines as well as the reference books regarding the pharmacological effects of HCQ.The results of this study suggested the following practical guidelines to optimize HCQ efficacy and safety in the management of COVID-19. HQC should be used as early as possible, i.e., once the viral infection is confirmed or suspected. A loading dose is recommended to be given in 3-4 divided doses to minimize cardiac toxicity. Maintenance daily dose (divided into two doses), should be continued until complete remission. Precautions,drug-interaction, contraindications, variable metabolic pathways in the particular population should be considered. This study suggests more clinical trials regarding the use of HCQ in the management of early identified COVID-19 patients under close medical observation to minimize HCQ cardiac toxicity

Effects of antimalarial drugs on mitochondrial respiration in erythrocytic stages of Plasmodium falciparum 3D7 / 中国临床药理学与治疗学

AIM: The Seahorse XFe96 analyzer was used to evaluate the effects of thirteen types of international first-line antimalarial drugs in six categories on the mitochondrial electron transport chain (ETC) of Plasmodium falciparum 3D7 (P. falciparum 3D7). METHODS: The antimalarial activity of in vitro drugs acting on P. falciparum 3D7 was evaluated using the three-day inhibition method and SYBR Green I fluorescence analysis method. MACS technology was used to separate and purify P. falciparum 3D7. The mitochondrial oxygen consumption rate (OCR) of Seahorse XF analysis system was used to characterize the bioenergy of P. falciparum 3D7 mitochondria at different times to investigate the effects of antimalarial drugs on mitochondrial aerobic respiration of Plasmodium falciparum. RESULTS: The results of flow cytometry showed that the Plasmodium of trophozoite stages was enriched successfully. The results of in vitro antimalarial activity evaluation showed that, except for the antimalarial drug proguanil (Pro), the other twelve antimalarial drugs were all of the nmol/L level against P. falciparum 3D7. The results of the mitochondrial aerobic respiration showed that the five concentrations of dihydroartemisinin (DHA) and chloroquine (CQ) (0.4, 1, 5, 10, 50×IC

Variation of cost among anti-malarial drugs available in Indian market

Background: There are numerous brands of antimalarial existent in the market. Expensive drugs could result in financial drain that causes reduced compliance or even non-compliance. Non-adherence to therapy could consequently cause partial treatment that leads to higher morbidity and in certain cases mortality too. Thus this evaluation was conducted to measure the cost disparity of malaria therapy.Methods: The maximum and minimum price of each brand of the drug in Indian rupee rate was noted by using the latest edition of current index of medical specialities. The cost ratio and the percentage cost variation for individual drug brands were calculated.Results: The analysis of data reflected a considerable cost variation among antimalarial drugs. Chloroquine DS 500 mg showed the highest cost ratio and cost variation (cost ratio=15.3 and % cost variation=1434). Overall injectable antimalarials showed considerable cost variation as compared to oral antimalarial agents.Conclusions: The maximum variation shown by oral antimalarial was found to be for chloroquine DS 500 tablet. But there was significant price variation among injectable antimalarial. Injectable antimalarials are often the choice of drug when dealing with critically ill malaria patients specially when suffering from complicated malaria. So, such significant price variation creates burden on poor patients economically which leads to non-compliance and hence increased morbidity and mortality due to incomplete treatment.

Evaluación de la proteólisis en células aisladas vivas de Plasmodium falciparum aisladas durante los estadios asexuales sanguíneos / Proteolysis assessment in isolated Plasmodium falciparum living cells at the asexual blood stages

It has been demonstrated that proteases play crucial roles in Plasmodium falciparum infection and therefore have been considered as targets for the development of new therapeutic drugs. The aim of this study was to describe the specific proteolytic activity profile in all blood stages of P. falciparum isolated parasites in order to explore new antimalarial options. For this purpose, we used the fluorogenic substrate Z-Phe-Arg-MCA (Z: carbobenzoxy, MCA: 7-amino-4-methyl coumarine) and classic inhibitors for the different classes of proteolytic enzymes, such as phenylmethylsulfonyl fluoride (PMSF), 1.10-phenantroline, pepstatin A and E64 to study the inhibition profiles. As expected, due to the high metabolic activity in mature stages, the substrate was mostly degraded in the trophozoite and schizont, with specific activities ~ 20 times higher than in early stages (merozoite/rings). The major actors in substrate hydrolysis were cysteine proteases, as confirmed by the complete hydrolysis inhibition with E64 addition. Proteolytic activity was also inhibited in the presence of PMSF in all but the schizont stage. However, PMSF inhibition was the result of unspecific interaction with cysteine proteases as demonstrated by reversion of inhibition by dithiotreitol (DTT), indicating that serine protease activity is very low or null. To our knowledge, this is the first report aiming to describe the proteolytic profile of P. falciparum isolated parasites at all the erythrocytic cycle stages. The results and protocol described herein can be useful in the elucidation of stage specific action of proteolysis-inhibiting drugs and aid in the development of antimalarial compounds with protease inhibitory activity(AU)

e ha demostrado que las proteasas desempeñan funciones vitales en la infección por Plasmodium falciparum, y por lo tanto se consideran dianas en la elaboración de nuevos medicamentos terapéuticos. El objetivo del estudio era describir el perfil de actividad proteolítica específica de todas las etapas sanguíneas de parásitos aislados de P. falciparum con vistas a explorar nuevas opciones antimaláricas. Con ese propósito, utilizamos el sustrato fluorogénico Z-Phe-Arg-AMC (Z: carbobenzoxi, AMC: 7-amino-4-metilcumarina) e inhibidores clásicos para las diferentes clases de enzimas proteolíticas, tales como el fluoruro de fenilmetilsulfonilo (PMSF), 1,10-fenantrolina, pepstatina A y E64 para estudiar los perfiles de inhibición. Como se esperaba, debido a la elevada actividad metabólica de las etapas de madurez, el sustrato fue degradado mayormente en el trofozoíto y el esquizonte, con actividad específica ~ 20 veces superior a la de las etapas tempranas (merozoíto/ anillos). Los principales actores en la hidrólisis del sustrato fueron las cisteínas proteasas, lo que fue confirmado por la inhibición completa de la hidrólisis con la adición de E64. La actividad proteolítica también fue inhibida en presencia de PMSF en todas las etapas excepto el esquizonte. Sin embargo, la inhibición del PMSF fue resultado de una interacción inespecífica con las cisteínas proteasas, según lo demuestra la reversión de la inhibición con el ditiotreitol (DTT), lo que indica que la actividad de la serina proteasa es muy baja o inexistente. Que sepamos, este es el primer informe dirigido a describir el perfil proteolítico de parásitos aislados de P. falciparum en todas las etapas del ciclo eritrocítico. Los resultados y el protocolo que aquí se describen pueden ser útiles para dilucidar la acción específica de los medicamentos inhibidores de proteólisis en cada etapa, así como contribuir al desarrollo de compuestos antimaláricos con actividad inhibidora de la proteasa(AU)

Prophylactic and Curative Potency of Alchornea laxiflora Extract on Plasmodium berghei Infected Swiss Albino Mice

Background:Malaria is one of the most important infectious diseases in Nigeria and in Africa at large as everyone is at risk of the infection. Objectives: This study was carried out to evaluate the antiplasmodial activity of Alchornea laxiflora leaf extracts against Plasmodium berghei infected mice. Materials and Methods:In vivoantimalarial assay on chloroquine-sensitive P. berghei-infected mice was carried out by oral administration of graded doses (200mg/kg, 400mg/kg and 600mg/kg) of methanolic and chloroform extracts using chloroquine and distilled water as positive and negative control respectively. Prophylactic potential in residual infection and curative assay against established infectionwere tested in P. berghei-infected mice. The assay was performed using 4-day suppressive standard test. Results:The prophylactic efficacy of methanolic and chloroform leaf extacts showed percentage chemosuppression of 72.37% and 66.32% respectively at oral dose of 600mg/kg. The methanol leaf extract of A. laxifloradisplayed the highest curative activity of percentage chemosuppression of 98.36% at oral dose of 600mg/kg. The extracts displayed dose-dependent significant (p ≤ 0.05 antiplasmodial activity as compared to the control. Haematological analysis revealed an increase in packed cell volume, red blood cell, haemoglobin and white blood cell counts on dose-dependent manner in the treated mice compared to the negative control mice. Conclusion:The high suppressive values obtained in this study show that the tested leaf extracts of Alchornea laxiflora might be a good alternative drug for the treatment of malaria infection in Nigeria.

Lupus erythematosus tumidus in childhood treated with antimalarials / Lupus eritematoso tumidus en la infancia tratado con antimalárico

Abstract Lupus erythematosus tumidus is a rare dermatosis. It is considered a subtype of chronic cutaneous lupus erythematosus of uncertain pathogenesis, favorable prognosis and rare association with systemic lupus erythematosus. Clinically, it manifests as urticarial-like plaques in photo exposed areas, mainly affecting adults, being extremely rare in pediatric age. Herein, we present two cases of six and nine-year-old male patients with clinical and histological characteristics typical of lupus erythematosus tumidus and poor response to first-line treatment (topical, intralesional steroids and topical calcineurin inhibitors); therefore, it was decided to start systemic therapy with antimalarials, obtaining a very good response.

Resumen El lupus eritematoso tumidus es una dermatosis poco frecuente. Es considerada una variante del lupus eritematoso cutáneo crónico, de patogénesis incierta, pronóstico favorable y rara asociación con lupus eritematoso sistémico. Clínicamente, se manifiesta como placas de aspecto urticarial en zonas fotoexpuestas, que principalmente afectan a los adultos, siendo extremadamente rara en edad pediátrica. A continuación presentamos dos casos de pacientes de sexo masculino de seis y nueve años, con características clínicas e histológicas típicas de lupus eritematoso tumidus y poca respuesta al tratamiento de primera línea (esteroides tópicos, intralesionales e inhibidores de calcineurina tópica), por lo que se decidió iniciar manejo sistémico con antimalárico, obteniendo muy buena respuesta terapéutica.

Discovery and Development of Artemisinin and Related Compounds / 中草药·英文版

Artemisinin is isolated from the plant Artemisia annua, sweet wormwood, an herb employed in traditional Chinese medicine. Prof. You-you Tu discovered artemisinin in the 1960s, so she was awarded the 2015 Nobel Prize in Physiology or Medicine. Artemisinin and its semi-synthetic derivatives are a group of drugs that possess the most rapid action of all current drugs against Plasmodium falciparum malaria. In this review, the author investigated history on discovery of artemisinin, ethnopharmacology of Artemisia plants, chemistry and pharmacological activities of the relative compounds, and introduced Tu and other Chinese and world scientists' contribution, development of artemisinin and the related compounds and registered and marketed artemisinin drugs in China, UK, and USA. The author also recalled the studies on the mechanism of action of artemisinins and artemisinin combination therapies and summed up the resistance issues. In Current Recommendations and the Global Plan for Insecticide Resistance Management in Malaria Vectors (GPIRM), that the WHO prevents the development and manages the spread of insecticide resistance is summarized in the technical basis for coordinated action against insecticide resistance: preserving the effectiveness of modern malaria vector control. Prof. Tu re-emphasized the artemisinin resistant on five principles to the WHO. She called on the world's scientists to pay attention to the study of drug resistance, and hopes scientists to contribute to break resistance of artemisinins.

Study of the antimalarial properties of hydroxyethylamine derivatives using green fluorescent protein transformed Plasmodium berghei

A rapid decrease in parasitaemia remains the major goal for new antimalarial drugs and thus, in vivo models must provide precise results concerning parasitaemia modulation. Hydroxyethylamine comprise an important group of alkanolamine compounds that exhibit pharmacological properties as proteases inhibitors that has already been proposed as a new class of antimalarial drugs. Herein, it was tested the antimalarial property of new nine different hydroxyethylamine derivatives using the green fluorescent protein (GFP)-expressing Plasmodium berghei strain. By comparing flow cytometry and microscopic analysis to evaluate parasitaemia recrudescence, it was observed that flow cytometry was a more sensitive methodology. The nine hydroxyethylamine derivatives were obtained by inserting one of the following radical in the para position: H, 4Cl, 4-Br, 4-F, 4-CH3, 4-OCH3, 4-NO2, 4-NH2 and 3-Br. The antimalarial test showed that the compound that received the methyl group (4-CH3) inhibited 70% of parasite growth. Our results suggest that GFP-transfected P. berghei is a useful tool to study the recrudescence of novel antimalarial drugs through parasitaemia examination by flow cytometry. Furthermore, it was demonstrated that the insertion of a methyl group at the para position of the sulfonamide ring appears to be critical for the antimalarial activity of this class of compounds.

Clinical spectrum, complications & treatment outcomes of malaria (in pediatric patients).

Malaria is one of the foremost public health problems in India. Objectives: To study the clinical spectrum, complications & treatment outcome in smear positive hospitalized children having malaria. Method: this prospective observational study enrolled 190 smear positive malaria patients admitted in pediatric wards of general hospital during 6 months. History taken & examination done. All patients were investigated & treated according to WHO guidelines & followed twice daily till their hospital stay. Results: 88% of patients were having P. vivax malaria. Males were 2.1 times more commonly affected. Age group most commonly affected was 5 to 10 years. Highest no of cases were reported in month of August. All patients were having history of fever. Thrombocytopenia was frequently associated (87%). Cerebral malaria was the commonest complication. Almost all patients with uncomplicated vivax malaria responded to Chloroquine. CFR was 1.05%.

Quality of essential drugs in tropical countries: evaluation of antimalarial drugs in the Brazilian Health System / Qualidade de medicamentos essenciais em países tropicais: avaliação de medicamentos antimaláricos no Sistema de Saúde do Brasil

INTRODUCTION: The emergence of drug resistance is one of the main problems concerning malaria treatment. The use of counterfeit and/or substandard antimalarial drugs can contribute to the development of parasite resistance. Thus, the aim of this study was to evaluate the quality of antimalarial drugs distributed in Brazil. METHODS: Samples containing chloroquine phosphate, mefloquine hydrochloride, primaquine phosphate, and quinine sulfate tablets were delivered to the Rio de Janeiro central storeroom (CENADI), state storerooms (SS), and Basic Health Units (BHUs) in the north region of Brazil - a total of 10 sample sets. After 5 months of storage, the samples were collected, and in vitro quality control analyses according to official and published methods were performed. RESULTS: Inadequate drug storage conditions were found in two SS and in all BHUs evaluated. There were no quality deviations found in the chloroquine samples. The quinine samples exhibited weight variation above the allowed limits. The primaquine samples were found to have packaging deficiency. The release of mefloquine in samples from some regions showed a statistically significant difference when compared with the CENADI samples. CONCLUSIONS: It is important to periodically evaluate the quality and storage conditions of essential drugs. The quality deviations found with the primaquine and quinine samples are not related to storage conditions and must be addressed urgently. The decreased mefloquine release from tablets is related to formulation problems or influenced by inadequate storage conditions, prompting further investigation. Even with the mentioned problems, the samples would probably not contribute to resistant parasite selection.

INTRODUÇÃO: O aparecimento de resistência aos medicamentos é um dos maiores problemas do tratamento da malária. O uso de medicamentos falsos e/ou de má qualidade pode contribuir para o desenvolvimento de resistência no parasita. Este estudo tem por objetivo avaliar a qualidade dos medicamentos antimaláricos distribuídos no Brasil. MÉTODOS: Amostras contendo comprimidos de difosfato de cloroquina, cloridrato de mefloquina, difosfato de primaquina e sulfato de quinina foram enviadas ao almoxarifado central na Cidade do Rio de Janeiro (CENADI), almoxarifados estaduais (SS) e Unidades Básicas de Saúde (UBS) nos estados da região norte do Brasil, totalizando dez amostras. Após cinco meses de armazenamento, as amostras foram coletadas e analisadas segundo métodos oficiais e da literatura. RESULTADOS: Foram encontradas condições inadequadas de armazenamento de medicamentos em duas SS e em todas as UBS avaliadas. Não foram encontrados problemas de qualidade com as amostras de cloroquina. As amostras de quinina apresentaram variação de peso acima dos limites permitidos. Amostras de primaquina foram encontradas com problemas na embalagem. A cedência de mefloquina de comprimidos, em algumas regiões, apresentou diferença estatisticamente significativa quando comparada com a amostra do CENADI. CONCLUSÕES: É importante avaliar, periodicamente, a qualidade e as condições de armazenamento de medicamentos essenciais. Desvios de qualidade encontrados com as amostras de primaquina e quinina não estão relacionados às condições de armazenamento e devem ser corrigidos urgentemente. O decréscimo na cedência de mefloquina dos comprimidos está relacionado com a formulação ou foi influenciada por condições de armazenamento inadequadas, necessitando de uma investigação posterior. Apesar dos problemas mencionados, as amostras provavelmente não contribuiriam para a seleção de parasitas resistentes.

Sentinel network for monitoring in vitro susceptibility of Plasmodium falciparum to antimalarial drugs in Colombia: a proof of concept

Drug resistance is one of the principal obstacles blocking worldwide malaria control. In Colombia, malaria remains a major public health concern and drug-resistant parasites have been reported. In vitro drug susceptibility assays are a useful tool for monitoring the emergence and spread of drug-resistant Plasmodium falciparum. The present study was conducted as a proof of concept for an antimalarial drug resistance surveillance network based on in vitro susceptibility testing in Colombia. Sentinel laboratories were set up in three malaria endemic areas. The enzyme linked immunosorbent assay-histidine rich protein 2 and schizont maturation methods were used to assess the susceptibility of fresh P. falciparum isolates to six antimalarial drugs. This study demonstrates that an antimalarial drug resistance surveillance network based on in vitro methods is feasible in the field with the participation of a research institute, local health institutions and universities. It could also serve as a model for a regional surveillance network. Preliminary susceptibility results showed widespread chloroquine resistance, which was consistent with previous reports for the Pacific region. However, high susceptibility to dihydroartemisinin and lumefantrine compounds, currently used for treatment in the country, was also reported. The implementation process identified critical points and opportunities for the improvement of network sustainability strategies.

A resistência à cloroquina e a busca de antimalariais entre as décadas de 1960 e 1980 / Chloroquine resistance and the search for antimalarial drugs from the 1960s to 1980s

Em 1961, a Organização Mundial de Saúde (OMS) reconheceu a resistência de cepas de Plasmodium à cloroquina, o que estimulou programas de pesquisa e desenvolvimento de novas drogas sintéticas que pudessem substituí-la no combate à malária. Analiso o processo de pesquisa científica relativo à produção de antimalariais nos contextos nacional e internacional, em especial nos EUA e na China, entre as décadas de 1960 e 1980. Pontos de convergência e distanciamento são marcados pelas dinâmicas próprias de cada país e pelos interesses envolvidos nas relações internacionais, em relação aos quais fica evidente o papel central da OMS.

Using High Performance Liquid Chromatography to quantitate Artemether and Artesunate anti-malarial tablets in the National Capital District, Papua New Guinea

Malaria is a major public health problem in Papua New Guinea (PNG). The Artemisinin-based combination therapy is widely used as the first-line treatment for malaria in PNG. This study was to assess the quantity of the Artemether and Artesunate ingredients in the antimalarial drugs used for the treatment of malaria in the National Capital District (NCD) PNG. Artemether and Artesunate tablets were purchased from various pharmacies in NCD. Artemether and Artesunate solutions were prepared according to the Standard United States Pharmacopoeial protocol for assay of active ingredients by high performance liquid chromatography (HPLC). The results indicated that the percent Artemether content in the three brands (ART 01, ART 02 and ART 03) of Artemether purchased in the NCD were 93.2%, 87.6% and 89.3% respectively. Four brands (ATS 01/02, ATS 03/04, ATS 05, and ATS 06) of Artesunate were purchased in the NCD. The % Artesunate content in the four brands were 109.0%, 110.0%, 101.2% and 96.2%% respectively. The three Artemether brands (100%) and two (ATS 01/02 and ATS 03/04) of the Artesunate brands (50%) did not satisfy the USP specifications for the amount of active ingredients in the drugs. Our data indicate that poor quality Artemether and Artesunate antimalarial drugs are sold in the National Capital District in PNG. This indicates the urgent need to advocate for more efficient drug monitoring and effective enforcement of regulations that prevents importation of substandard drugs into the NCD.

In vitro effect of current antimalarial drugs on the survival of paired Schistosoma mansoni adult worms and their egg production

Some field trials have already demonstrated the high antischistosomal potential of combination therapies using Artesunate (ART) and current antimalarial drugs (Boulanger <I>et al.,</I> 2007; Mohamed <I>et al.,</I> 2009; Sissoko <I>et al.,</I> 2009). The antischistosomal effects of these drugs are noteworthy, especially when they are used for the treatment of malaria in schistosomiasis endemic areas. However, the antischistosomal effects of Amodiaquine (AQ), Primaquine (PQ), Chloroquine (CQ) and Pyrimethamine (Py) have never been assessed by <I>in vitro</I> incubation. The objective of the present study is to assess the <I>in vitro</I> effects of current antimalarial drugs on the egg productivity of adult worm pairs of <I>S. mansoni</I> and their survival times. The effect of the current antimalarial drugs Mefloquine (MQ), quinine (QN), AQ, PQ, CQ, Sulfadiazine (Sf) and Py on the egg output of adult worm pairs of <I>Schistosoma mansoni</I> and their survival times during <I>in vitro</I> culture were assessed at a concentration of 10 Μg⁄ml. AQ, PQ, CQ and Py significantly inhibited the daily egg output of paired female worms at a concentration of 10 Μg⁄ml during the 1 or 2-day <I>in vitro</I> cultivation. However, QN and Sf did not significantly affect the daily egg output during the 8-day incubation. One-day exposure to MQ killed all paired male and female adult worms. AQ and PQ significantly decreased the survival of both paired male and female worms during the 14-day incubation, but QN, CQ, Py and Sf did not exert any similar effect. The present result is consistent with an assessment of the antischistosomal effects of artemisinin-based combination therapy in malaria and schistosomiasis co-endemic areas.

Evaluación de la eficacia de la cloroquina para eltratamiento de la malaria por Plasmodium vivax enYacuiba, Tarija, Bolivia / Evaluation of the chloroquine efficacy for the treatment of malaria by Plasmodium vivax in Yacuiba, Tarija, Bolivia

Se realizó una evaluación in vivo de la eficacia de la cloroquina para el tratamiento de la malaria por Plasmodium vivax, en elsitio centinela de Palmar Chico, Municipio de Yacuiba, Provincia Gran Chaco, Departamento de Tarija al Sur de Bolivia. Fueronincluidos en el estudio 61 pacientes entre 5 y 59 años de edad que presentaban monoinfección por P. vivax. Todos los pacientesrecibieron una dosis total de cloroquina de 25 mg/Kg en 3 días (10mg/Kg el primer día; 7,5 mg/Kg el segundo y tercer días).De acuerdo al protocolo estandarizado de la OPS/OMS, todos los pacientes fueron seguidos por 28 días (controles clínicos yparasitológicos). Se completó el seguimiento de 60 pacientes, ninguno de los pacientes tuvo recurrencias de la parasitemia opresentó manifestaciones clínicas después del tercer día de tratamiento. Este estudio mostró 100% de sensibilidad de P. vivaxa la cloroquina, lo que justifica su permanencia en la política de medicamentos antimaláricos como la droga más adecuada parael tratamiento de las infecciones por P. vivax en el Sur de Bolivia.

We carried out an evaluation in vivoof the chloroquine efficacy for the treatment of malaria by Plasmodium vivax, in the sentinelsite of Palmar Chico, Municipality of Yacuiba, Province Gran Chaco, Department of Tarija to the South of Bolivia. Sixty one patientsaged between 5 and 59 years that presented monoinfection by P. vivaxwere included in the study. All patient received undersupervision a total dose of chloroquine 25mg/kg over three days (10mg/kg on the first day; 7.5 mg/kg on the second and thirddays). According the standardized protocol of the PAHO/WHO, all patients were followed-up for 28 days (clinical and parasitologicalcontrols). Sixty patients completed the follow-up, none of the patients had recurrences of parasitemia or presented clinicalmanifestations after third day of treatment. This study showed 100% of sensibility from P. vivax to chloroquine, what justifies theirpermanency in the antimalarial drug policy as the most adequate drug for the treatment of the P. vivax infections in the South of Bolivia.

NUEVAS VÍAS DE PERMEABILIDAD Y REGULACIÓN DEL pH INTRACELULAR COMO POSIBLES BLANCOS TERAPÉUTICOS EN Plasmodium falciparum / The New Permeability Pathways And Cytosolic pH: Targets For Antimalarial Agents On Plasmodium falciparum

Actualmente, existe una necesidad sentida para el desarrollo de nuevos fármacos antimaláricos o de compuestos conocidos dirigidos contra blancos terapéuticos diferentes a los afectados por los medicamentos usuales. Son diversos los blancos que pueden ser aprovechados en Plasmodium, y la alteración de parámetros fisiológicos como el pH y el transporte de solutos pueden explicar la muerte del parásito cuando se usan compuestos antiplasmodiales, lo que representa una opción para el desarrollo de nuevas alternativas antiparasitarias. El propósito de esta revisión es por tanto, proporcionar una visión general de los efectos causados por esteroides, discutiendo el caso específico de los esteroides antiplasmodiales aislados de Solanum nudum y revisar dos procesos fisiológicos importantes en el parásito como posibles blancos terapéuticos, la modificación de permeabilidad del eritrocito infectado y el mantenimiento del pH intracelular de Plasmodium.

In malaria, attention has been posed to search or develop new antimalarial drugs or their modifications against different therapeutic targets in P. falciparum. Therapeutic targets such physiological parameters and solute transport have been proposed to kill the parasite and they represent an option for development of new drugs. We present a review on the effects of steroids, in particular the antiplasmodial steroids isolated from Solanum nudum, stressing two physiological Plasmodium processes such as the new permeability pathways on the infected red blood cells and the cytosolic pH regulation.

Coadaptation and malaria control

Malaria emerges from a disequilibrium of the system 'human-plasmodium-mosquito' (HPM). If the equilibrium is maintained, malaria does not ensue and the result is asymptomatic plasmodium infection. The relationships among the components of the system involve coadaptive linkages that lead to equilibrium. A vast body of evidence supports this assumption, including the strategies involved in the relationships between plasmodium and human and mosquito immune systems, and the emergence of resistance of plasmodia to antimalarial drugs and of mosquitoes to insecticides. Coadaptive strategies for malaria control are based on the following principles: (1) the system HPM is composed of three highly complex and dynamic components, whose interplay involves coadaptive linkages that tend to maintain the equilibrium of the system; (2) human and mosquito immune systems play a central role in the coadaptive interplay with plasmodium, and hence, in the mainten-ance of the system's equilibrium; the under- or overfunction of human immune system may result in malaria and influence its severity; (3) coadaptation depends on genetic and epigenetic phenomena occurring at the interfaces of the components of the system, and may involve exchange of infectrons (genes or gene fragments) between the partners; (4) plasmodia and mosquitoes have been submitted to selective pressures, leading to adaptation, for an extremely long while and are, therefore, endowed with the capacity to circumvent both natural (immunity) and artificial (drugs, insecticides, vaccines) measures aiming at destroying them; (5) since malaria represents disequilibrium of the system HPM, its control should aim at maintaining or restoring this equilibrium; (6) the disequilibrium of integrated systems involves the disequilibrium of their components, therefore the maintenance or restoration of the system's equilibrium depend on the adoption of integrated and coordinated measures acting on all components,...

Disponibilidad y uso de medicamentos antimaláricos en Bolivia / Availability and use of drugs im Bolivia antimaláricos

Pregunta de investigación ¿Como es la disponibilidad y el uso de los antimaláricos en Bolivia? Objetivos. Evaluar la disponibilidad y uso de los medicamentos antimaláricos en zonas endémicas de malaria de acuerdo a las normas nacionales. Métodos. Siguiendo los indicadores pre diseñados del manual de gestión farmaceutica de la malaria del management for Sciencies health (MSH). fue evaluada la disponibilidad de los antimaláricos revisando registros 2004-2005 de 21 establecimientos de salud de nivel I y II además de 4 almacenes regionales de los departamentos de Beni, Pando y Tarija y uno del nivel central (La Paz). Para evaluar el uso de los antimaláricos se utilizó la misma herramienta revisando 780 casos de malaria de los registros de tratamiento de pacientes con malaria no complicada atendidos durante el mismo periodo, tambien se observaron 156 atenciones a pacientes con malaria no complicada, habiendose entrevistado a 146 de ellos (93 por ciento) inmediatamente despues de recibir el tratamiento, asi como tambien se realizaron compras de antimaláricos en 28 farmacias privadas de los mismos departamentos. Resultados. El 76 por ciento (5/21) de los establecimientos evaluados no tienen registro de entrada y salida de medicamentos, la disponibilidad de medicamentos antimaláricos para malaria por P. vivax es del 100 por ciento, malaria no complicada por P.falciparum 53 por ciento, malaria y embarazo por P. falciparum 3 por ciento y malaria grave por P. falciparum 0 por ciento en los establecimientos de salud mientras que en los almacenes evaluados es el 90 por ciento, 25 por ciento, 25 por ciento y 38 por ciento respectivamente. los almacenes con mayor tiempo de desabastecimiento (365 días) fueron el de Riberalta y Guayaramerin para el artesunato,clindamicina y biclorhidrato ...

Research question How is it the availability and the use of antimalarial drugs in Bolivia?Objective Evaluate the availability and the use of antimalarial drugs in endemic areas of malaria according to the national norms.METHODS Following the indicator pre-designed in the manual of pharmaceutical management of the malaria of the Management for Sciences Health, the availability of the antimalarial drugs was evaluated revising the registers 2004-2005 of 21 health’s establishments level I and II and 4 regional depots of the Departments of Beni, Pando y Tarija. To...